Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATHA

ATHA - Athira Pharma Inc Stock Price, Fair Value and News

3.93USD+0.23 (+6.22%)Market Closed
Watchlist

Market Summary

USD3.93+0.23
Market Closed
6.22%

ATHA Stock Price

View Fullscreen

ATHA RSI Chart

ATHA Valuation

Market Cap

136.7M

Price/Earnings (Trailing)

-1.16

Price/Sales (Trailing)

26.48

Price/Free Cashflow

-1.35

ATHA Price/Sales (Trailing)

ATHA Profitability

Return on Equity

-90.39%

Return on Assets

-73.43%

Free Cashflow Yield

-73.95%

ATHA Fundamentals

ATHA Revenue

Revenue (TTM)

5.2M

ATHA Earnings

Earnings (TTM)

-117.7M

Earnings Growth (Yr)

9.46%

Earnings Growth (Qtr)

17.24%

Breaking Down ATHA Revenue

Last 7 days

7.8%

Last 30 days

19.3%

Last 90 days

111.8%

Trailing 12 Months

6.2%

How does ATHA drawdown profile look like?

ATHA Financial Health

Current Ratio

5.37

ATHA Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-3.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20229.2M7.9M6.5M5.2M
20213.2M5.1M7.0M8.8M
2020895.8K1.0M1.2M1.3M
2019000754.0K

Tracking the Latest Insider Buys and Sells of Athira Pharma Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 05, 2024
worthington mark
sold
-7,018
2.91
-2,412
general counsel
Jan 05, 2024
litton mark james
sold
-14,026
2.91
-4,820
chief executive officer
Jan 05, 2024
lenington rachel
sold
-7,018
2.91
-2,412
coo and cdo
Jan 05, 2024
litton mark james
sold
-14,026
2.91
-4,820
ceo
Jan 05, 2024
lenington rachel
sold
-7,018
2.91
-2,412
chief operating officer
Jan 05, 2024
church kevin
sold
-7,018
2.91
-2,412
chief scientific officer
Jan 05, 2024
worthington mark
sold
-7,018
2.91
-2,412
general counsel
Jan 05, 2024
gengos andrew
sold
-3,515
2.91
-1,208
cfo and chief business officer
Jan 04, 2024
lenington rachel
acquired
-
-
10,000
coo and cdo
Jan 04, 2024
worthington mark
acquired
-
-
10,000
general counsel

1–10 of 50

Which funds bought or sold ATHA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
1.28
131,000
731,000
0.06%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
sold off
-100
-19,000
-
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-60.16
-458,000
422,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
55,351
55,351
-%
Feb 15, 2024
Potomac Capital Management, Inc.
added
100
212,830
363,492
0.42%
Feb 14, 2024
Verition Fund Management LLC
unchanged
-
41,000
243,000
-%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
added
6.99
161,816
725,598
-%
Feb 14, 2024
Cubist Systematic Strategies, LLC
reduced
-14.06
1,344
41,023
-%
Feb 14, 2024
Squarepoint Ops LLC
sold off
-100
-22,095
-
-%
Feb 14, 2024
Point72 Asia (Singapore) Pte. Ltd.
new
-
7,472
7,472
-%

1–10 of 45

Are Funds Buying or Selling ATHA?

Are funds buying ATHA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATHA
No. of Funds

Unveiling Athira Pharma Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
baker bros. advisors lp
8.3%
3,153,807
SC 13G
Dec 29, 2023
perceptive advisors llc
14.2%
5,402,964
SC 13D/A
Jul 07, 2023
blackrock inc.
1.8%
669,768
SC 13G/A
Apr 20, 2023
kayne richard a
5.3%
1,983,668
SC 13G
Feb 14, 2023
rtw investments, lp
0%
0
SC 13G/A
Feb 01, 2023
blackrock inc.
6.2%
2,363,221
SC 13G/A
Jan 30, 2023
franklin resources inc
0.0%
0
SC 13G/A
Jul 01, 2022
perceptive advisors llc
12.8%
4,811,149
SC 13D/A
Feb 14, 2022
rtw investments, lp
5.1%
1,906,557
SC 13G/A
Feb 14, 2022
venrock healthcare capital partners ii, l.p.
2.7%
1e+06
SC 13G/A

Recent SEC filings of Athira Pharma Inc

View All Filings
Date Filed Form Type Document
Feb 22, 2024
10-K
Annual Report
Feb 22, 2024
8-K
Current Report
Feb 22, 2024
S-8
Employee Benefits Plan
Feb 16, 2024
4/A
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4/A
Insider Trading

Peers (Alternatives to Athira Pharma Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Athira Pharma Inc News

Latest updates
Simply Wall St16 Feb 202411:02 am

Athira Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue---1,227,0002,959,0002,596,5002,234,0002,336,0002,079,0002,589,000------
Costs and Expenses6.3%31,640,00029,770,00032,927,00024,133,00023,569,00023,387,00018,778,00017,826,00016,637,00010,781,0009,079,0007,397,0002,252,0001,267,0001,117,000
  S&GA Expenses18.3%10,025,0008,477,0007,691,0007,168,0008,766,0008,927,0006,160,0007,119,0004,613,0003,336,0003,892,0001,567,000575,000675,000459,000
  R&D Expenses1.5%21,615,00021,293,00015,236,00016,965,00014,803,00014,460,00012,618,00010,707,00012,024,0007,445,0005,187,0005,830,0001,677,000592,000658,000
Net Income-6.4%-29,597,000-27,820,000-30,135,000-20,189,000-24,335,000-20,980,000-16,339,000-15,674,000-13,974,000-8,866,000-7,702,000-8,456,000-1,992,000-1,805,000-974,000
Net Income Margin-5.1%-20.88-19.86-18.53-12.55-9.81-7.25-6.21-6.64-7.68-8.44-15.11-11.22---
Free Cashflow8.0%-24,315,000-26,435,000-15,668,000-21,884,000-18,741,000-17,317,000-19,204,000-10,427,000-7,431,000-7,609,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-13.2%160185208233258274292313332347360369280268-------
  Current Assets-13.3%155179192193208229256269261239290312192232--2.00---5.00
    Cash Equivalents-17.9%91.0011011410596.0087.0095.0011811110713212861.00166--2.00---3.00
  Net PPE-6.7%3.004.004.004.004.004.004.004.004.003.003.003.003.001.00-------
Liabilities0.4%30.0030.0023.0022.0023.0012.0011.0011.0011.0011.009.006.005.008.007.006.005.004.004.003.003.00
  Current Liabilities0.8%29.0029.0022.0020.0021.0010.0010.009.009.009.008.004.004.008.00--1.00---1.00
Shareholder's Equity-15.9%13015518521123526228130232133635136327425912.002.001.001.001.00-1.00
  Retained Earnings-9.7%-309-281-248-219-191-161-141-116-95.89-79.56-63.88-49.91-41.04-33.34---21.09----15.93
  Additional Paid-In Capital0.5%440437435432429426424420417416415413315293--1.00---1.00
Shares Outstanding0.3%38.0038.0038.0038.0038.0038.0038.0038.0037.0037.0036.0036.0032.00--------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-9.6%-26,293-23,984-24,282-26,194-15,667-21,640-18,590-16,572-18,177-10,299-7,317-7,305-10,665-9,411-2,862-1,175-1,029----
  Share Based Compensation-10.7%2,2282,4943,1192,7822,3602,4203,0952,7311,4351,1051,10997441511149.0058.0064.00----
Cashflow From Investing-69.1%6,39120,69032,48635,52224,64713,632-4,46123,84621,373-14,19911,455-22,708-115,758-94,3132.001.00751----
Cashflow From Financing-152-24299.00147-29721013.00125-26097,21121,323184,28385,3041,84054.00----

ATHA Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 27,202$ 16,965$ 70,110$ 46,228
General and administrative7,8407,16826,34224,861
Total operating expenses35,04224,13396,45271,089
Loss from operations(35,042)(24,133)(96,452)(71,089)
Grant income 2,9591573,934
Other income, net2,0729855,9081,651
Net loss(32,970)(20,189)(90,387)(65,504)
Unrealized gain (loss) on available-for-sale securities261(547)1,278(2,084)
Comprehensive loss attributable to common stockholders$ (32,709)$ (20,736)$ (89,109)$ (67,588)
Net loss per share attributable to common stockholders, basic$ (0.87)$ (0.53)$ (2.38)$ (1.74)
Net loss per share attributable to common stockholders, diluted$ (0.87)$ (0.53)$ (2.38)$ (1.74)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic38,054,58337,817,72437,993,00237,693,830
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted38,054,58337,817,72437,993,00237,693,830

ATHA Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 110,334$ 95,966
Short-term investments62,614104,378
Unbilled grant receivable 1,227
Prepaid expenses and other current assets5,5565,962
Total current assets178,504207,533
Restricted cash631420
Property and equipment, net3,6334,053
Operating lease right-of-use asset1,1051,263
Long-term investments 44,829
Other long-term assets82755
Total assets184,700258,153
Current liabilities:  
Accounts payable1,7112,501
Accrued liabilities16,5538,604
Accrued legal settlement10,00010,000
Current operating lease liability358326
Total current liabilities28,62221,431
Operating lease liability, less current portion1,3141,585
Total liabilities29,93623,016
Stockholders' equity:  
Common stock, $0.0001 par value; 900,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 38,054,583 and 37,877,387 shares issued and outstanding at September 30, 2023 and December 31,2022, respectively44
Additional paid-in capital437,359428,623
Accumulated other comprehensive loss(678)(1,956)
Accumulated deficit(281,921)(191,534)
Total stockholders' equity154,764235,137
Total liabilities and stockholders' equity$ 184,700$ 258,153
ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
 CEO
 WEBSITEwww.athira.com
 EMPLOYEES63

Athira Pharma Inc Frequently Asked Questions


What is the ticker symbol for Athira Pharma Inc? What does ATHA stand for in stocks?

ATHA is the stock ticker symbol of Athira Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Athira Pharma Inc (ATHA)?

As of Thu Feb 22 2024, market cap of Athira Pharma Inc is 149.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATHA stock?

You can check ATHA's fair value in chart for subscribers.

What is the fair value of ATHA stock?

You can check ATHA's fair value in chart for subscribers. The fair value of Athira Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Athira Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATHA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Athira Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether ATHA is over valued or under valued. Whether Athira Pharma Inc is cheap or expensive depends on the assumptions which impact Athira Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATHA.

What is Athira Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ATHA's PE ratio (Price to Earnings) is -1.24 and Price to Sales (PS) ratio is 23.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATHA PE ratio will change depending on the future growth rate expectations of investors.